Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Star Health Insurance is modernising its claims ecosystem to be future-ready
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Dilip Shanghvi to continue as the Executive Chairman of the Board
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Subscribe To Our Newsletter & Stay Updated